- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05048966
Comparaison de deux interventions de mieux-être en groupe pour les personnes atteintes de troubles neurologiques et leurs personnes de soutien
Comparaison de deux interventions de bien-être de groupe pour les personnes atteintes de troubles neurologiques et leurs personnes de soutien : un essai clinique randomisé
Approximately 5.3 million people live with a long-term disability resulting from a traumatic brain injury (TBI) and between 5-8% of those older than 60 suffer from Alzheimer's disease or other forms of dementia (ADRD). Consequences of these conditions can result in dramatic and persistent changes in functioning, impacting not only the patients, but also loved ones who become informal support persons. Many existing services help the family in the moment, but do not address long-term wellness. Thus, the purpose of this research study is to compare the effect of two different types of group wellness treatments for individuals with chronic mild TBI, moderate to severe TBI, and ADRD and their support persons.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study will involve three sites, with a different clinical population targeted at each site. Kessler Foundation will serve as the Coordinating Center and will enroll individuals with moderate/severe TBI. Indiana University and University of Michigan will serve as partnering sites and will enroll individuals with chronic mild TBI and ADRD respectively. The research protocols at each site will be unique to the patient population, but harmonized through unified project goals: 1) to evaluate the efficacy of two different online group wellness treatments designed to improve self-efficacy and quality of life, and 2) to determine whether patient neurobehavioral functioning moderates the relationship between treatment outcomes and burden in caregivers, and 3) to determine the neural, behavioral, and blood biomarkers that best predict treatment efficacy. It is expected that findings generated from this study will lead to improved holistic approaches for brain injury and dementia systems of care.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Diana Maloku, B.S.
- Numéro de téléphone: 973-324-8393
- E-mail: dmaloku@kesslerfoundation.org
Lieux d'étude
-
-
New Jersey
-
East Hanover, New Jersey, États-Unis, 07936
- Recrutement
- Kessler Foundation
-
Contact:
- Matthew Weiner
- Numéro de téléphone: 973-324-3515
- E-mail: mweiner@kesslerfoundation.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
For individuals with moderate/severe TBI:
Inclusion Criteria:
- age 18-70
- at least 4 months post injury
- can read and speak English fluently
- has a support person who is willing to participate in the study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than TBI
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For individuals with chronic mild TBI:
Inclusion Criteria:
- age 18-70
- at least 3 months post-injury
- can read and speak English fluently
- has a support person who is willing to participate in the study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than mild TBI
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For Individuals with Alzheimer's Disease Related Dementias (ADRD)
Inclusion Criteria:
- age 65 and older
- at least one-year post-diagnosis
- can read and speak English fluently
- has a support person who is willing to participate in this study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than ADRD
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For Support Persons:
Inclusion Criteria:
- is the support person of an individual with moderate/severe TBI, chronic mild TBI or ADRD who is willing to participate in the study
- can read and speak English fluently
Exclusion Criteria:
- has a significant neurological history (e.g. stroke or multiple sclerosis)
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group Wellness Class 1
|
Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours. |
|
Comparateur actif: Group Wellness Class 2
|
Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change on Self-Efficacy Questionnaire (SEQ)
Délai: 12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
self-report instrument that assesses an individual's and support person's self-efficacy as it relates to their ability to manage the effects of the neurologic conditions on their daily functioning |
12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
|
Change on Satisfaction with Life Scale (SWLS)
Délai: 12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
self-report measure that examines life satisfaction component of subjective well-being and quality of life |
12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Les troubles mentaux
- Blessures et Blessures
- Troubles neurocognitifs
- Tauopathies
- Maladies neurodégénératives
- Traumatisme crânio-cérébral
- Traumatisme, système nerveux
- Blessures à la tête, fermé
- Blessures non pénétrantes
- Lésions cérébrales
- Lésions cérébrales, traumatiques
- Maladie d'Alzheimer
- Commotion cérébrale
- Démence
Autres numéros d'identification d'étude
- R-1157-21
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .